First patient enrolled in melanoma study

Pierre Fabre and the European Organisation for Research and Treatment of Cancer (EORTC) have announced the screening of the first patient with a resected stage II BRAF-mutant melanoma for the Phase III study COLUMBUS-AD.

read more